By Neil Kubica, John Blenis (auth.), Vitaly A. Polunovsky, Peter J. Houghton (eds.)
mTOR Pathway and mTOR Inhibitors in melanoma treatment offers an updated survey of the swiftly advancing box of melanoma treatment. Our figuring out of the mechanisms serious about melanoma genesis and development underwent extraordinary enlargement over the last decade, establishing a brand new period of melanoma therapy – designated remedy. The surge during this region leads to no small half from experiences performed together by way of easy overall healthiness scientists and medical investigators. it truly is our desire that this publication can assist foster even extra collaboration among investigators in those disciplines. during this paintings, specialists in TOR signaling have contributed in thematic parts: mTOR Signaling and melanoma treatment (chapters 1 - eight) and healing concentrating on Downstream of mTOR (chapter nine – 13). All chapters of mTOR Pathway and mTOR Inhibitors in melanoma remedy are thoroughly new or were widely up-to-date by way of their authors; and we're indebted to all authors who've exemplified the hyperlinks among those 2 thematic areas.
Read Online or Download mTOR Pathway and mTOR Inhibitors in Cancer Therapy PDF
Similar oncology books
Energy Balance and Gastrointestinal Cancer
The gastrointestinal music offers one of many precise structures the place a number of malignancies, together with adenocarcinoma of the pancreas, esophagus and colon are each one linked to weight problems. This particular organization is roofed during this quantity of strength stability and melanoma from the epidemiologic, biologic and power etiologic standpoint.
Brain Metastases from Primary Tumors. Epidemiology, Biology, and Therapy
With an annual fee of greater than 12 million worldwide diagnoses and seven. 6 million deaths, the societal and fiscal burden of melanoma can't be overstated. mind metastases are the commonest malignant tumors of the significant anxious procedure, but their prevalence seems to be expanding regardless of the development of melanoma treatments.
Branching Process Models of Cancer
This quantity develops effects on non-stop time branching procedures and applies them to review cost of tumor development, extending vintage paintings at the Luria-Delbruck distribution. for this reason, the writer calculate the chance that mutations that confer resistance to therapy are current at detection and quantify the level of tumor heterogeneity.
- Brody's Human Pharmacology
- Renal Cancer: Methods and Protocols (Methods in Molecular Medicine)
- Infectious Agents and Cancer
- The Molecular Basis of Cancer
Extra resources for mTOR Pathway and mTOR Inhibitors in Cancer Therapy
Sample text
Chen EJ, Kaiser CA (2003) LST8 negatively regulates amino acid biosynthesis as a component of the TOR pathway. J Cell Biol 161:333–347 34. Yang Q, Guan KL (2007) Expanding mTOR signaling. Cell Res 17:666–681 35. Shiota C, Woo JT, Lindner J, Shelton KD, Magnuson MA (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11:583–589 36. Bayascas JR, Wullschleger S, Sakamoto K et al (yr) Mutation of PDK1 PH domain inhibits PKB/Akt leading to small size and insulin-resistance.
When yTORC1 is inactivated, activated YAK1 phosphorylates CRF1, inducing nuclear translocation and repression of FHL1. While a detailed description of transcriptional regulation by yTORC1 is beyond the scope of this chapter, a common feature highlighted by the above examples is re-distribution of transcription factors between the nuclear and cytoplasmic compartments. In addition to the positive role of yTORC1 on transcription factors, yTOR also modifies RP gene expression by regulating chromatin remodeling.
Dan HC, Sun M, Yang L et al (2002) Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277:35364–35370 70. Liu MY, Cai S, Espejo A, Bedford MT, Walker CL (2002) 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res 62:6475–6480 71. Nellist M, Goedbloed MA, de Winter C et al (2002) Identification and characterization of the interaction between tuberin and 14-3-3zeta. J Biol Chem 277:39417–39424 72.